Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells
Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a heterogeneous disease course. There is no cure for SLE, but current standard pharmacotherapies can improve disease prognosis in most patients. However, some patients are refractory to conv...
Saved in:
Main Authors: | Lihui Wen, Myriam Labopin, Manuela Badoglio, Dandan Wang, Lingyun Sun, Dominique Farge-Bancel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2019/7061408 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of TNF-α with Impaired Migration Capacity of Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus
by: Linyu Geng, et al.
Published: (2014-01-01) -
Umbilical Cord-Derived Mesenchymal Stem Cells Suppress Autophagy of T Cells in Patients with Systemic Lupus Erythematosus via Transfer of Mitochondria
by: Jinyun Chen, et al.
Published: (2016-01-01) -
Systemic Lupus Erythematosus
by: Chaim Putterman, et al.
Published: (2012-01-01) -
Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses
by: Sean D. Owens, et al.
Published: (2016-01-01) -
Lupus Enteritis as an Initial Presentation of Systemic Lupus Erythematosus
by: Sisira Sran, et al.
Published: (2014-01-01)